Abstract |
Many drugs and chemicals found in the environment are either detoxified by N-acetyltransferase 1 (NAT1, EC 2.3.1.5) and eliminated from the body or bioactivated to metabolites that have the potential to cause toxicity and/or cancer. NAT1 activity in the body is regulated by genetic polymorphisms as well as environmental factors such as substrate-dependent down-regulation and oxidative stress. Here we report the molecular mechanism for the low protein expression from mutant NAT1 alleles that gives rise to the slow acetylator phenotype and show that a similar process accounts for enzyme down-regulation by NAT1 substrates. NAT1 allozymes NAT1 14, NAT1 15, NAT1 17, and NAT1 22 are devoid of enzyme activity and have short intracellular half-lives ( approximately 4 h) compared with wild-type NAT1 4 and the active allozyme NAT1 24. The inactive allozymes are unable to be acetylated by cofactor, resulting in ubiquitination and rapid degradation by the 26 S proteasome. This was confirmed by site-directed mutagenesis of the active site cysteine 68. The NAT1 substrate p-aminobenzoic acid induced ubiquitination of the usually stable NAT1 4, leading to its rapid degradation. From this study, we conclude that NAT1 exists in the cell in either a stable acetylated state or an unstable non-acetylated state and that mutations in the NAT1 gene that prevent protein acetylation produce a slow acetylator phenotype.
|
Authors | Neville J Butcher, Ajanthy Arulpragasam, Rodney F Minchin |
Journal | The Journal of biological chemistry
(J Biol Chem)
Vol. 279
Issue 21
Pg. 22131-7
(May 21 2004)
ISSN: 0021-9258 [Print] United States |
PMID | 15039438
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cysteine Proteinase Inhibitors
- DNA, Complementary
- Isoenzymes
- Leupeptins
- Multienzyme Complexes
- Protein Synthesis Inhibitors
- Recombinant Proteins
- Ubiquitin
- Cycloheximide
- Arylamine N-Acetyltransferase
- N-acetyltransferase 1
- Glutathione Transferase
- Peptide Hydrolases
- Cysteine Endopeptidases
- Proteasome Endopeptidase Complex
- ATP dependent 26S protease
- Cysteine
- benzyloxycarbonylleucyl-leucyl-leucine aldehyde
- 4-Aminobenzoic Acid
|
Topics |
- 4-Aminobenzoic Acid
(pharmacology)
- Alleles
- Arylamine N-Acetyltransferase
(metabolism)
- Binding Sites
- Blotting, Western
- Cell Line, Tumor
- Cloning, Molecular
- Cycloheximide
(pharmacology)
- Cysteine
(chemistry)
- Cysteine Endopeptidases
(metabolism)
- Cysteine Proteinase Inhibitors
(pharmacology)
- DNA, Complementary
(metabolism)
- Down-Regulation
- Escherichia coli
(metabolism)
- Genotype
- Glutathione Transferase
(metabolism)
- Humans
- Isoenzymes
(metabolism)
- Leukocytes, Mononuclear
(metabolism)
- Leupeptins
(pharmacology)
- Models, Biological
- Multienzyme Complexes
(metabolism)
- Mutagenesis, Site-Directed
- Mutation
- Oxidative Stress
- Peptide Hydrolases
(chemistry)
- Phenotype
- Precipitin Tests
- Proteasome Endopeptidase Complex
- Protein Binding
- Protein Synthesis Inhibitors
(pharmacology)
- Recombinant Proteins
(metabolism)
- Time Factors
- Ubiquitin
(metabolism)
|